Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
January 22, 2026
Approximately 5 minutes
TGA Procedure for Recalls, Product Alerts and Product Corrections
TGA Procedure for Recalls, Product Alerts and Product Corrections
Overview
The TGA oversees post-market actions when therapeutic goods (medicines, biologicals, medical devices, IVDs) pose actual or potential safety risks. Sponsors must initiate and coordinate recalls, alerts or corrections, with TGA oversight to ensure appropriate risk mitigation.
Risk Classification
Actions are classified by potential patient harm:
- Class I: Reasonable probability of serious adverse health consequences or death.
- Class II: Temporary or medically reversible adverse health consequences; remote probability of serious harm/death.
- Class III: Unlikely to cause adverse health consequences, but product does not conform to standards.
Classification guides urgency, communication scope, and reporting requirements.
Types of Actions
- Recall: Removal of goods from supply chain and user level due to safety risk.
- Product Alert: Notification to users/healthcare professionals about risks without full removal (e.g., usage restrictions).
- Product Correction: Repair, modification, adjustment, relabelling, or advisory notice to address non-conformance or risk.
Key Steps in the Process
- Sponsor identification: Detect issue via complaints, testing, vigilance reports, or international alerts.
- Risk assessment: Evaluate hazard severity, probability, and affected population.
- Consult TGA: Discuss proposed action, classification, and strategy before public communication.
- Strategy development: Define scope (batch/lot/serial), depth (wholesale, retail, user), communication plan, and effectiveness checks.
- TGA agreement: Obtain TGA concurrence on classification and strategy.
- Implementation:
- Notify consignees/users (urgent for Class I).
- Publish TGA recall/alert notice on website.
- Recover/repair/replace goods as required.
- Effectiveness verification: Confirm action completion and risk resolution.
- Closure: TGA confirms satisfactory completion; sponsor provides final report.
Sponsor Responsibilities
- Initiate action promptly upon identifying risk.
- Maintain records of distribution to facilitate traceability.
- Provide regular progress updates to TGA.
- Cover costs of recall/correction.
- Report outcomes and any further incidents.
TGA Role
- Provide guidance and technical input.
- Assess and agree on classification/strategy.
- Publish public notices for transparency.
- Monitor compliance and effectiveness.
- Enforce if sponsor fails to act adequately.
Detailed classification criteria, communication templates, reporting timelines, effectiveness check methods, and examples of past actions are provided in the TGA procedure for recalls, product alerts and product corrections. Source: Procedure for recalls, product alerts and product corrections - TGA
This risk-based system ensures rapid, proportionate response to safety issues while protecting Australian patients and maintaining supply chain integrity.
Ask Anything
We'll follow up with you personally.
Related Articles
Approximately 5 minutes
Varying Your Medical Device or IVD ARTG Entry – TGA Variation Process
Sponsors of medical devices and in vitro diagnostic (IVD) products included in the Australian Register of Therapeutic Goods (ARTG) must apply to the Therapeutic Goods Administration (TGA) for any variation that affects the device's characteristics, intended purpose, labelling, or other entry details. Variations are classified as administrative, minor, or major, with corresponding application requirements, fees, and assessment timelines to ensure continued compliance and safety.
Approximately 5 minutes
Withdrawing Your Medical Device or IVD ARTG Application – TGA Guidelines
The Therapeutic Goods Administration (TGA) allows sponsors to voluntarily withdraw a pending application for inclusion of a medical device or in vitro diagnostic (IVD) in the Australian Register of Therapeutic Goods (ARTG) at any time before a decision is made. Withdrawal is a simple administrative process that stops further assessment and avoids fees if done early, while ensuring the application is no longer active.
Approximately 5 minutes
TGA Actions to Address EU MDR-Related Medical Device Supply Shortages
The TGA has introduced targeted exemptions, prioritised reviews, and supply monitoring to prevent shortages of medical devices in Australia caused by manufacturers discontinuing supply due to the stricter EU Medical Device Regulation (MDR) and IVDR requirements.
Approximately 5 minutes
Overview of Supplying Therapeutic Goods in Australia – TGA Requirements
Supplying therapeutic goods (medicines, biologicals, medical devices, and IVDs) in Australia requires inclusion in the Australian Register of Therapeutic Goods (ARTG), compliance with relevant standards, and adherence to sponsor responsibilities including labelling, advertising, and post-market obligations to ensure safety, quality, and efficacy.